US 10,376,595 B2
Treatment of inflammatory diseases with inhibitors of C5a activity
Renfeng Guo, Ann Arbor, MI (US); and Niels C. Riedemann, Jena (DE)
Assigned to InflaRx GmbH, Jena (DE)
Filed by InflaRx GmbH, Jena (DE)
Filed on Jun. 13, 2018, as Appl. No. 16/7,340.
Application 16/007,340 is a continuation of application No. PCT/EP2018/050146, filed on Jan. 3, 2018.
Claims priority of application No. 17164573 (EP), filed on Apr. 3, 2017; application No. 17177657 (EP), filed on Jun. 23, 2017; and application No. 17189938 (EP), filed on Sep. 7, 2017.
Prior Publication US 2018/0280530 A1, Oct. 4, 2018
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 47/68 (2017.01); A61K 31/711 (2006.01); A61K 39/395 (2006.01); A61P 17/00 (2006.01); C07K 16/18 (2006.01); C07K 16/28 (2006.01); C07K 16/40 (2006.01); A61K 39/00 (2006.01)
CPC A61K 47/6807 (2017.08) [A61K 31/711 (2013.01); A61K 39/3955 (2013.01); A61P 17/00 (2018.01); C07K 16/18 (2013.01); C07K 16/2896 (2013.01); C07K 16/40 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/55 (2013.01); C07K 2317/76 (2013.01)] 19 Claims
 
1. A method of treating Hidradenitis suppurativa (HS) or a HS-related disease in a subject, the method comprising: administering to the subject in need thereof an effective amount of an agent that inhibits C5a activity in the subject, wherein the HS-related disease is selected from the group consisting of Pyoderma gangrenosum (PG); PASH (PG, acne and Hidradenitis suppurativa); and PAPASH (Pyogenic arthritis, acne, PG and Hidradenitis suppurativa).